FidoCure Unleashes Fetch™: AI Engine Analyzes Real-World Evidence To Optimize Cancer Therapies for Dogs

PALO ALTO, Calif.--(BUSINESS WIRE)--FidoCure, a leader in precision oncology for dogs, launched Fetch™, its proprietary artificial intelligence engine. As dogs increasingly become cherished family members, they face a critical challenge: cancer remains the leading cause of death, with few therapeutic options available. Through Fetch, FidoCure aims to address this problem by analyzing large datasets of real-world canine cancer cases to identify promising therapies for dogs with cancer.

Fetch analyzes two billion data points, from the world’s largest clinico-genomic canine cancer database, to identify novel connections between targeted therapies and the genetic profiles of cancer. Built by FidoCure through comprehensive genomic data collection from nearly 6,000 dogs, the rich dataset powers Fetch’s ability to predict optimal targeted therapies for specific canine cancers. This ability to uncover and prioritize new cancer treatment opportunities is unprecedented in the pet industry, which is expected to grow to $500 billion by 2030.

"This first-in-class approach is transformative," explained Professor James Zou, a leading researcher in AI for healthcare at Stanford University who helped develop Fetch. "Traditional targeted therapies focus on specific genetic markers, while Fetch can uncover new patterns that expand the applicability of these treatments.”

Fetch’s predictive power to improve pet patient outcomes was recently demonstrated through FidoCure's newly secured patent, a novel targeted therapy and biomarker for canine bladder cancer. The new therapy was developed through Fetch's analysis of biomarker characteristics against its vast dataset, which precisely identified the optimal targeted therapy candidate. This achievement—the first patent granted using artificial intelligence to determine canine cancer treatment protocols—highlights how Fetch is already yielding tangible results in identifying new opportunities for canine cancer therapies.

"Dogs are beloved family members, and they deserve access to personalized cancer care with a level of precision that was previously impossible," said Christina Lopes, CEO and Founder of FidoCure.

With Fetch designed to address the unique genetic profiles of cancer, FidoCure is advancing its mission to transform cancer from a death sentence into a second chance at life for dogs.

ABOUT FIDOCURE BY THE ONE HEALTH COMPANY

FidoCure is an AI-driven precision oncology company that is transforming cancer care for dogs. FidoCure has created the world’s largest canine cancer dataset, with over 2 billion data points collected from patients treated in its network of 1,350 veterinary clinics. Learn more at www.fidocure.com.